<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-11-20</loc>
      <lastmod>2026-11-22T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-22T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Five Under 5: Top Oncology Videos for the Week of 11/20]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-11-15</loc>
      <lastmod>2026-11-21T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-21T13:00:00Z</news:publication_date>
        <news:title><![CDATA[The OncFive: Top Oncology Articles for the Week of 11/15]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-gutierrez-on-considerations-for-investigating-sar445877-in-mss-crc</loc>
      <lastmod>2026-11-20T21:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T21:30:00Z</news:publication_date>
        <news:title><![CDATA[Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/daraxonrasib-plus-gemcitabine-nab-paclitaxel-generates-durable-responses-in-first-line-metastatic-pdac</loc>
      <lastmod>2026-11-20T21:25:46.715Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T21:25:46.715Z</news:publication_date>
        <news:title><![CDATA[Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/trofuse-015-meets-primary-os-end-point-with-sac-tmt-in-third-line-or-later-gastroesophageal-adenocarcinoma</loc>
      <lastmod>2026-11-20T20:42:43.169Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T20:42:43.169Z</news:publication_date>
        <news:title><![CDATA[TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-iyengar-on-oral-serd-implementation-in-early-stage-hr-breast-cancer</loc>
      <lastmod>2026-11-20T18:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T18:05:00Z</news:publication_date>
        <news:title><![CDATA[Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/squamous-biology-emerging-targets-and-trop2-antibody-drug-conjugates</loc>
      <lastmod>2026-11-20T17:40:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:40:00Z</news:publication_date>
        <news:title><![CDATA[Squamous Biology, Emerging Targets, and TROP2 Antibody-Drug Conjugates]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/progression-patterns-and-real-world-docetaxel-experience</loc>
      <lastmod>2026-11-20T17:35:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:35:00Z</news:publication_date>
        <news:title><![CDATA[Progression Patterns and Real-World Docetaxel Experience]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-leighl-on-harmoni-survival-data-and-the-fda-s-decision-on-ivonescimab-in-previously-treated-egfr-mutated-nsclc</loc>
      <lastmod>2026-11-20T17:17:30.979Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:17:30.979Z</news:publication_date>
        <news:title><![CDATA[Dr Leighl on HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-dos-anjos-on-how-access-and-cost-shape-breast-cancer-treatment-in-brazil</loc>
      <lastmod>2026-11-20T17:10:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:10:00Z</news:publication_date>
        <news:title><![CDATA[Dr dos Anjos on How Access and Cost Shape Breast Cancer Treatment in Brazil ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/faq-experts-tackle-key-questions-on-mapk-directed-therapy-frontline-parp-inhibitor-maintenance-and-adcs-in-ovarian-cancer</loc>
      <lastmod>2026-11-20T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Experts Tackle Key Questions on MAPK-Directed Therapy, Frontline PARP Inhibitor Maintenance, and ADCs in Ovarian Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/onclive-weekly-news-quiz-11-20-2026-did-you-miss-crucial-lung-cancer-pcnsl-gastroesophageal-cancer-and-aml-updates-</loc>
      <lastmod>2026-11-20T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T14:00:00Z</news:publication_date>
        <news:title><![CDATA[OncLive Weekly News Quiz (11/20/2026): Did You Miss Crucial Lung Cancer, PCNSL, Gastroesophageal Cancer, and AML Updates?]]></news:title>
      </news:news>
	</url></urlset>